Señales en vivo de 4743.TWO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 01:30):

Stats
Volumen de hoy	1.51M
Volumen promedio	2.17M
Capitalización de mercado	71.79B
EPS	TWD0 ( 2024-03-05 )
Próxima fecha de ganancias	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-48.02
ATR14	TWD0.185 (0.12%)

Volumen Correlación

Largo: -0.08 (neutral)

Corto: 0.00 (neutral)

Signal:(35.335) Neutral

Oneness Biotech Co., Ltd. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oneness Biotech Co., Ltd. Correlación - Moneda/Commodity

0.57
( weak )

0.53
( weak )

0.00
( neutral )

0.56
( weak )

-0.63
( weak negative )

-0.65
( weak negative )

Oneness Biotech Co., Ltd. Finanzas

Annual	2023
Ingresos:	TWD86.78M
Beneficio Bruto:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2023
Ingresos:	TWD86.78M
Beneficio Bruto:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2022
Ingresos:	TWD1.07B
Beneficio Bruto:	TWD844.39M (79.24 %)
EPS:	TWD0.820

FY	2021
Ingresos:	TWD65.77M
Beneficio Bruto:	TWD45.04M (68.49 %)
EPS:	TWD-1.060

Financial Reports:

No articles found.

Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.